{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:26:37Z","timestamp":1760243197647},"reference-count":10,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2020,8,1]]},"DOI":"10.1001\/jamadermatol.2020.0894","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T17:00:30Z","timestamp":1586970030000},"page":"837","source":"Crossref","is-referenced-by-count":7,"title":["Gene Expression Profile Testing for Thin Melanoma"],"prefix":"10.1001","volume":"156","author":[{"given":"Carrie L.","family":"Kovarik","sequence":"first","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily Y.","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adewole S.","family":"Adamson","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dell Medical School, The University of Texas at Austin"},{"name":"LIVESTRONG Cancer Institutes, The University of Texas at Austin"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"4","key":"dvp200003r1","doi-asserted-by":"publisher","first-page":"450","DOI":"10.6004\/jnccn.2016.0051","article-title":"Melanoma, version 2.2016, NCCN Clinical Practice Guidelines in Oncology.","volume":"14","author":"Coit","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"dvp200003r2","doi-asserted-by":"publisher","first-page":"308","DOI":"10.6004\/jnccn.2009.0023","article-title":"Role of sentinel lymph node biopsy in patients with thin melanoma.","volume":"7","author":"Andtbacka","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"dvp200003r3","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jaad.2018.08.055","article-title":"Guidelines of care for the management of primary cutaneous melanoma.","volume":"80","author":"Swetter","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"dvp200003r4","first-page":"291","article-title":"Appropriate use criteria for the integration of diagnostic and prognostic gene expression profile assays into the management of cutaneous malignant melanoma: an expert panel consensus-based modified Delphi process assessment.","volume":"3","author":"Berman","year":"2019","journal-title":"Skin (Los Angeles)"},{"issue":"1","key":"dvp200003r5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jaad.2018.07.028","article-title":"Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria.","volume":"80","author":"Gastman","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"dvp200003r6","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1016\/j.jaad.2018.11.063","article-title":"Use of a prognostic gene expression profile test for T1 cutaneous melanoma: will it help or harm patients?","volume":"80","author":"Marchetti","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"dvp200003r7","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene signature as an aid to treatment decisions in early-stage breast cancer.","volume":"375","author":"Cardoso","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"dvp200003r8","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.2217\/fon-2018-0912","article-title":"Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling.","volume":"15","author":"Vetto","year":"2019","journal-title":"Future Oncol"},{"issue":"4","key":"dvp200003r9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.25251\/skin.3.4.2","article-title":"Establishing an evidence-based decision point for clinical use of the 31-gene expression profile test in cutaneous melanoma.","volume":"3","author":"Marks","year":"2019","journal-title":"Skin"},{"key":"dvp200003r10","unstructured":"Centers for Medicare & Medicaid Services. Local coverage determination (LCD): MolDX: DecisionDx-Melanoma (L37725) [date in effect: February 3, 2020]. Accessed February 3, 2020. https:\/\/www.cms.gov\/medicare-coverage-database\/"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2764606\/jamadermatology_kovarik_2020_vp_200003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T01:41:53Z","timestamp":1597282913000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2764606"}},"subtitle":["Evidence to Support Clinical Use Remains Thin"],"short-title":[],"issued":{"date-parts":[[2020,8,1]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2020.0894","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,1]]}}}